Operations Maturity Audit — Biotech

What this audit examines in Biotech

• AI-native R&D capability — the computational biology, generative chemistry, target ID, and lead optimization infrastructure that absorbs the AI-native competitor capability into the existing regulated R&D engine.
• Clinical operations modernization — the recruitment optimization, site selection, trial monitoring, and data management infrastructure that compresses the largest cost line in the R&D budget.
• Regulatory documentation and writing platform — the generative writing copilots, evidence assembly, and audit-readiness infrastructure that lifts the medical writing function from constraint to capability.
• Translational and biomarker AI — the multi-omic, patient-stratification, and biomarker infrastructure that improves trial design and probability of technical success across the portfolio.